CIA
TVTX icon

Cape Investment Advisory’s Travere Therapeutics TVTX Stock Holding History

Cape Investment Advisory’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.61K Buy
+46
New +$2.04K ﹤0.01% 1184
2026
Q1 		– Sell
-45
Closed -$1.72K – 1129
2025
Q4 		$1.72K Buy
+45
New +$1.46K ﹤0.01% 1126

Other funds holding TVTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Cape Investment Advisory's TVTX Position: Q2 2026 in Review

Cape Investment Advisory opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 46 shares worth $2.61K. The stake represents ﹤0.01% of the portfolio and ranks #1184 among its holdings. This is a return to the name: Cape Investment Advisory previously reported a position in TVTX as recently as Q4 2025.

Cape Investment Advisory first reported a position in TVTX in Q4 2025 and has held it in 2 quarters since. 110 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Cape Investment Advisory held 46 shares of Travere Therapeutics worth $2.61K as of Q2 2026.
  • Travere Therapeutics was a new Cape Investment Advisory position in Q2 2026.
  • Travere Therapeutics made up ﹤0.01% of Cape Investment Advisory's portfolio in Q2 2026, its #1184 holding.
  • Cape Investment Advisory first reported a position in Travere Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 110 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Cape Investment Advisory's 13F filing for Q2 2026, filed 23 Jul 2026.